Daily filing brief

10 Important BSE and NSE Announcements — 12 August 2026

Here are 10 notable company announcements from 12 August 2026. The brief brings the key developments together in one place and keeps the essential details easy to scan.

By Daily BrieferPublished

  1. Apollo Hospitals Enterprise Ltd

    Apollo Hospitals Q1 FY27: Revenue up 21%, EBITDA up 28%, PAT up 34%, HealthCo composite scheme outlined

    Investor Presentation

    Business overview

    • Core business spans Healthcare Services, Diagnostics & AHLL, and Digital Health & Pharmacy Distribution via Apollo HealthCo.
    • AHLL's Mother & Child and Fertility units to combine into a major maternity platform.
    • Apollo HealthCo is the omni-channel platform integrating digital and offline healthcare services.

    Operational highlights

    • Commissioned five new hospitals in the last two quarters.
    • Total census beds after expansion ~14,100.
    • Current beds at Q1FY27: 9,857.
    • Expansion plan adds about 1,000 census beds; total project cost ₹11,150 cr, ₹7,500 cr remaining.
    • Geographic expansion across Pune, Delhi, Hyderabad, Kolkata, and other Tier-1/Tier-2 cities.
    • Of 1,000 beds, 380 operational; 620 to be activated in 12–18 months.

    Financial performance

    • Consolidated revenue ₹70,435 mn; YoY growth 21%.
    • Consolidated EBITDA ₹10,920 mn; margin 15.5%.
    • PAT ₹5,805 mn; growth 34%.
    • ROCE 28.5% in Q1FY27.
    • Hospital segment occupancy 70% established units; average revenue per in-patient ₹186,630.

    Capital structure & liquidity

    • Cash and equivalents ₹23,560 mn; liquid funds ₹18,555 mn.
    • Consolidated net debt ₹7,481 mn.

    Strategic priorities & outlook

    • Composite scheme approved; demerger of OCP and Apollo 24x7 into NewCo; amalgamation with Keimed.
    • Listing expected by Q4 FY27.
    • Target run-rate revenue ₹250 bn; EBITDA margin 6.5–7.0%.
    • Plan bolt-on acquisitions in Tier-1 cities.

    Risks & mitigation

    • Execution risk in phased 1,000-bed expansion.
    • Integration risk from HealthCo demerger and amalgamation.
    • One-time network investment impacting margins.

    Governance & leadership

    • Shareholder approvals secured for composite scheme; NewCo listing.
    • NewCo to be Indian-owned and controlled (IOCC) post approvals.
    • Automatic listing of NewCo; AHEL shareholders directly participate.
    • Post-merger listing expected by Q4 FY27.
    Read the primary exchange filing

  2. Ola Electric Mobility Ltd

    MHI revises ACC PLI timelines for Ola Electric; secures full five-year incentives through CY2031, up to ₹7,240 crore

    Press Release / Media Release

    PLI timeline revision and incentives

    • MHI approves revised ACC PLI timelines for Ola Cell Technologies, securing five-year PLI window through CY2031.
    • Cumulative PLI incentives up to ₹7,240 crore; disbursements quarterly beginning next quarter.
    • Current installed cell capacity at Ola Electric: 2.5 GWh.
    • Additional 3.5 GWh under installation; total 6 GWh by end of current quarter.
    • Five-year window extends original timeline by two years.
    • Roadmap includes Shakti and Mahashakti energy products; broader energy platform underway.
    Read the primary exchange filing

  3. Lupin Ltd

    Lupin posts record Q1 FY2027 revenue and EBITDA; US growth solid, full-year EBITDA guidance around 25%.

    Earnings Call Transcript

    Financial Performance

    • Q1 FY27 revenue from operations: INR 8,277 crores; EBITDA ex-forex/other income: INR 2,464 crores.
    • Revenue grew 32% YoY; EBITDA grew 50% YoY; 16th consecutive YoY growth.
    • Gross margin at 74.6% in Q1; up 330 bps vs Q1 FY26.
    • EBITDA margin was 30% in Q1; full-year target around 25%.
    • R&D spend 7.4% of sales; INR 608 crores.
    • Other operating income: INR 60 crores; down 43% YoY due to lower export benefits.
    • Operating working capital: INR 8,260 crores; 90 days of net working capital.
    • Net cash: INR 2,831 crores as of 30 June 2026; 4,636 crores as of 31 March 2026.
    • ROCE: 29.5%; FY26 was 28.4%.
    • ESG progress: 41% GHG reduction, 45% water recycling; TIME sustainability list recognition.

    Geography & Segments

    • U.S. sales: USD 366 million in Q1; CC growth 30% YoY.
    • FY27 U.S. revenue target: USD 1.1–1.2 billion.
    • India sales: INR 2,380 crores; 13.9% YoY; core prescription growth 15.1%.
    • Volume growth in India: 6.1%; chronic share ~67% of portfolio.
    • Other Developed Markets: INR 1,149 crores; 14% of sales; YoY +48%; Europe +83%.
    • Emerging Markets: INR 990 crores; YoY +52%; Brazil +117% local currency.

    Pipeline & Product Launches

    • Pegfilgrastim launch expected in H2 FY27; 505(b)(2) Dalbavancin in pipeline.
    • Nasal Fluticasone spray; Epinephrine nasal spray; Raltegravir; Eribulin; Diazepam nasal spray in FY27.
    • FY28: Apixaban 505(b)(2); Diazepam nasal; Epinephrine nasal; iron sucrose; Saxenda; Ivacaftor FTF.
    • FY29: Spiriva Respimat filing; Etanercept; potential P4-related timing.
    • Xywav is a FY33 product; MDI capacity is fungible across products.

    Guidance & Outlook

    • Near-term US headwinds from Tolvaptan and Mirabegron; growth moderates.
    • FY27 US revenue guidance anchored at USD 1.1–1.2 billion.
    • Full-year EBITDA margins expected around 25%.
    • R&D spend 7.4% of sales; ETR expected 27–28%.
    • US growth to resume from FY28; 50+ US products in pipeline.

    Risks & Watchpoints

    • US competition in Tolvaptan and Mirabegron could pressure margins.
    • Geopolitical headwinds and FX volatility remain risk factors.
    • Export benefits under PLI schemes declined; impact on Other Operating Income.
    • FDA EIRs received for Ankleshwar and Somerset; Pithampur remediation ongoing.
    Read the primary exchange filing

  4. Black Box Ltd

    Black Box reports Q1 FY27 revenue ₹1,719 crore, backlog US$949 million; FY27 orders guidance US$1.3-1.5B

    Press Release / Media Release

    Financial highlights

    • Q1 FY27 revenue ₹1,719 crore, up 24% YoY
    • EBITDA ₹160 crore, margin 9.3%, up 90 bps
    • PAT ₹56 crore, up 18% YoY
    • Order backlog US$949 million (~₹8,986 crore), up 83% YoY
    • New orders during quarter US$339 million (~₹3,208 crore)

    Backlog and bookings outlook

    • Backlog at quarter-end US$949 million; project-led backlog up ~50% QoQ
    • FY27 order bookings guidance US$1.3-1.5 billion (growth ~32-45% vs FY26)
    • End-FY27 backlog target US$1.3-1.4 billion (up 65-75% YoY)

    Strategic developments

    • New global hyperscaler order worth US$131 million
    • Gigawatt-scale data centre programs; India-origin AI-led provider
    • Plan to hire ~3,000 professionals by FY30, mainly in the U.S.
    • Aims to reach US$2 billion revenue by FY30

    Market and execution momentum

    • Demand broad-based across financial services, healthcare, public services, retail
    • Approximately 300 strategic enterprise accounts engaged
    Read the primary exchange filing

  5. Aster DM Quality Care Ltd

    Aster DM Quality Care Q1 FY27: revenue up 20%, EBITDA up 30%, synergy-led margin path to 24-25%

    Earnings Call Transcript

    Financial Performance

    • Combined Q1 FY27 revenue: INR 2,597 crores, up 20% YoY (proforma).
    • EBITDA: INR 576 crores, up 30% YoY; margin 22.2%.
    • Aster standalone Q1 FY27 revenue: INR 1,311 crores; EBITDA 277 crores; margin 21.1%.
    • Normalised PAT up 39% YoY to ~INR 125 crores; merger costs INR 114 crores (one-time).
    • RoCE improved to 22.6% from 20.7%.

    Operating Update

    • Mature units contribute 73% of revenue; EBITDA margins 30%.
    • Focus units 15% of revenue; revenue up 16%; EBITDA margin +60 bps.
    • Emerging segment revenue up 63% YoY; EBITDA up 240%; margins 12.4% (640 bps).
    • Kasaragod facility breakeven in June 2026 after nine months of operation.
    • Robotics volumes grew ~80% YoY; joint replacements +39%; transplants +19%.
    • Care Hi-Tech earned JCI accreditation; ET Brand of the Year; NABH/Medical Dialogues recognitions.
    • Platform served nearly 8 million patients in 12 months; 39 hospitals, 28 cities, 9 states; 7,400+ clinicians.
    • 159-bed Aster Women & Children block commissioned at Whitefield in Apr 2026.

    Balance Sheet and Cash Flow

    • Combined net debt: INR 1,162 crores as of 30 Jun 2026.
    • Aster net cash: INR 511 crores; Quality Care debt: INR 1,673 crores.

    Capex and Expansion

    • Bed addition target: 4,170 beds in 3-4 years; total beds >15,000; 53% brownfield.
    • 159-bed Aster Women & Children block commissioned at Whitefield.
    • Trivandrum hospital to operate H2 FY27; Hyderabad by Apr 2027; Sarjapur Phase I by H2 FY28.

    Guidance and Outlook

    • EBITDA margin target 24-25% in 2-3 years post-merger.
    • Synergies to deliver 10-15% incremental EBITDA on FY24 pro forma EBITDA; starting this financial year.
    • MVT growth >50%; target mid-single to double-digit contribution over time.
    • Brand unification not decided; multiple brands may continue.

    Q&A Highlights

    • Synergy realization starts this year; target 10-15% incremental EBITDA.
    • Maturity framework defines four categories: mature, focus, emerging, underperforming.
    • Kerala performance strong; Kasaragod break-even in June 2026 after nine months.
    • Trivandrum, Hyderabad, Sarjapur project timelines updated.
    • Brand strategy not decided; plan to leverage market strengths.
    • EBITDA margin target reaffirmed at 24-25% in 2-3 years post-merger.
    • MVT growth agenda; share to mid-single digits then double-digit.
    Read the primary exchange filing

  6. GMR Airports Ltd

    GMR Airports reports Q1FY27 results; revenue up 23%, PAT positive; Nagpur handover completed

    Press Release / Media Release

    Financial highlights

    • Q1FY27 total income up 23% YoY to INR 4,085 crore.
    • EBITDA up 22% YoY to INR 1,568 crore.
    • PAT stood at INR 148 crore; fourth consecutive positive quarter.

    Portfolio expansion & milestones

    • Nagpur handover completed on 25 Jun 2026; modernization planned.
    • Bhogapuram inaugurated on 1 Aug 2026; commercial operations to commence soon.
    • Mopa on-site packhouse being established to enable incremental perishable exports.

    Strategic MRO agreement

    • GMR Aero Technic signed license with Honeywell for 7 LEAP LRU MRO.
    • Scope includes disassembly, inspection, repair, reassembly, and functional testing.

    Credit rating upgrade

    • CARE upgraded GAL rating to A+ (Positive) from A (Stable) for INR 15bn NCBs and long-term facilities.
    • Short-term rating upgraded to A1+ from A1.

    Q1 airport performance highlights

    • Delhi: 20.4 million passengers in Q1FY27.
    • Hyderabad: 7.1 million passengers; quarterly SPP INR 956.
    • Mopa Goa: 1.16 million passengers; total income INR 126 crore.
    Read the primary exchange filing

  7. Pidilite Industries Ltd

    Pidilite Q1 FY27: Standalone revenue up 22%, exports weak; margins expand; growth engines advance.

    Earnings Call Transcript

    Financial Performance

    • Standalone revenue: INR 4,237 crores, up 22.2%, volume growth 11.3%.
    • Consolidated revenue: INR 4,541 crores, up 21.3%; EBITDA margin +120 bps; PAT +30.3%.
    • Gross margin 52.5%, down 90 bps YoY; EBITDA margin 26.4%, up 80 bps QoQ.
    • Domestic subsidiaries revenue grew 11.5%; international subsidiaries grew 12%.

    Exports and Pricing

    • B2B exports UVG stood at -8.4% in Q1; overall exports degrew due to geopolitics.
    • Pricing: Consumer & Bazaar price increases near 10% in the quarter.
    • Pricing varies by category and brand; some rebates; inventory carryover occurred.
    • VAM prices fluctuated; management proactive pricing based on replacement margins.

    Growth and Innovations

    • Fevicol X-PER and M-Seal washable described as core innovations.
    • UnoFin progress: green shoots; no fixed target disclosed.
    • Electronics adhesives focus expanding to auto and EV segments; some commercial traction.
    • Waterproofing: Dr. Fixit momentum; projects and retail growth; trained applicators ecosystem.

    Market and Competition

    • Tile adhesives face rising competition from cement and tile manufacturers.
    • Pidilite’s moat: broad plant network, consistent quality, and Total Delivered Cost focus.
    • Waterproofing leadership via Dr. Fixit; emphasis on systems and trained installers.

    Guidance and Outlook

    • Guidance: maintain margin corridor; no change to guidance at this stage.
    • Demand remains robust; management saw no demand impact from pricing actions to date.
    • First-half focus on growth; double-digit underlying volume growth target implied.

    Q&A Highlights

    • Exports expected to rebound as geopolitical conditions stabilize.
    • Pricing increases largely completed by June; demand unchanged.
    • UnoFin progress: green shoots; no fixed target disclosed.
    • Tile adhesives competition; moat from plant network and consistent quality.
    • Margins: corridor maintained; first-half margin expected to be stronger.
    • Electronics adhesives: progress expanding into auto/EV; some commercial traction.
    Read the primary exchange filing

  8. Multi Commodity Exchange of India Ltd

    MCX Q1 FY27: 85% income rise to INR 752 cr; Silver 100g futures launched; RBI bank-guarantee impact modest

    Earnings Call Transcript

    Financial Performance

    • Total income rose 85% YoY to INR 752 crores in Q1 FY27.
    • Notional Options ADT grew 266% in the quarter.
    • Traded client base doubled to 13.72 lakh in Q1 FY27.
    • Float income for the quarter was around INR 30 crores.
    • Q1 electricity futures ADT approx INR 37 crores; market share about 55%.
    • Employee cost includes a one-time 8-9% rise; not expected to recur.

    Operating Update

    • Silver 100 Grams Futures launched due to market demand.
    • 50+ AMCs now reference MCX bullion price for AUM calculations.
    • Silver Good Delivery norms expanded; domestic silver refiner empanelled.
    • Three more domestic gold refiners empanelled; framework extended across all contracts.
    • Coal Exchange of India incorporated; regulator approvals pending.
    • MCX remains world's largest commodity options exchange; 4th largest by contracts traded.

    Technology & Capacity

    • Tech capacity to handle over 3 billion transactions daily; potential to double capacity.
    • Risk management remains top priority; focus on scale and resiliency.

    Q&A Highlights

    • RBI bank guarantees in force; impact expected modest; cost of funds may rise gradually.
    • SEBI commodity derivatives: timelines on open items not disclosed.
    • Electricity futures: Q1 ADT is INR 37 crores; market share about 55%.
    • 12 new members joined in the quarter.
    • 35 new FPIs; total FPIs around 220.
    • FPI contribution about 2.5% of revenue.
    • Crude/energy volumes volatile; bullion volumes softer in June.
    • 8-10% of daily electricity needs transacted on spot exchanges; derivative growth expected.
    • Competition rising; 12 new members and 35 FPIs joined.
    Read the primary exchange filing

  9. Kaynes Technology India Ltd

    Kaynes Technology India Q1 FY27: EMS-led 40% revenue rise; OSAT/PCB capex on track amid balance-sheet discipline

    Earnings Call Transcript

    Financial Performance

    • Q1 FY27 revenue 946 crores; YoY growth 40%, EMS-led.
    • EBITDA 147.6 crores; margin 15.6%; YoY EBITDA growth 31%.
    • EMS revenue 854 crores; EMS collections 847 crores; GridCrest revenue 240 crores; GridCrest collections 88 crores.
    • Cash from operations negative ~INR 259 crores; inventory up INR 150 crores.
    • Receivables from leading EV customer below INR 100 crores.
    • Total debt around INR 800 crores; debt-to-equity ~0.3.
    • Profitability to normalize in two quarters as supply-chain costs stabilize.
    • Acquisition of August Electronics completed; North American expansion gaining traction.

    Operating Update

    • OSAT and PCB ramp-up on track; operational by Q3 FY27.
    • PCB capacity fully booked by a large global customer; trials ongoing; vendor code issued.
    • Mitsui-Kaynes Semicon partnership established; access to Japan market.
    • Space tech: first 3U satellite prototype ready; launch mid-next year; ISRO date pending.
    • DRDO and Crio Aerotech to manufacture titanium gas bottles for flight programs.

    Balance Sheet and Cash Flow

    • Receivables from leading EV customer reduced below INR 100 crores.
    • Inventory up by INR 150 crores to support future quarters.
    • Tax rate company ~22–23%; consolidated ~35%.
    • Debt around INR 800 crores; long-term funding not drawn yet.
    • Rolling 12-month view to be shared for working capital metrics.

    Projects and Capex

    • FY26 capex: OSAT 473 crores; PCB 324 crores.
    • FY27 capex target: OSAT 300 crores; PCB 300 crores; EMS 250 crores.
    • Government subsidy OSAT ~INR 170 crores received till July 2026.
    • OSAT-Mitsui partnership significantly milestones; access to Japan market.
    • PCB: trials ongoing; production planned next quarter; large EV customer engaged.
    • In-transit inventory around INR 250 crores.

    Guidance and Outlook

    • FY27 OSAT+PCB revenue target INR 450–500 crores.
    • Market growth was ~17% in Q1; company targets ~2x market growth.
    • OSAT/PCB revenue to start in Q3 and Q4; full-year target remains.
    • Profitability expected to normalize in 2 quarters; margins under pressure from inputs.
    • Cash-positive by year-end FY27.

    Q&A Highlights

    • EMS growth 40%; metering growth 28%; EMS revenue 854 crores; EMS collections 847 crores.
    • OSAT/PCB commercial revenue bookings targeted for Q3 and Q4 FY27.
    • Inventory and receivables elevate CFO decline; steps to mitigate impact discussed.
    • Order book > INR 8,900 crores in system; execution momentum noted.
    • Pricing pressures in PCB and component shortages cited; margins may compress short term.

    Risks and Watchpoints

    • Working capital intensity with higher receivables and inventory; supply-chain lead times.
    • PCB pricing pressures and component shortages; potential margin compression.
    • Strategic option to divest metering service component being evaluated.
    Read the primary exchange filing

  10. Inox Wind Ltd

    INOX Wind & INOX Green Q1 FY27: 4.4 GW backlog, 872 cr revenue, 59% equipment mix; guidance intact.

    Earnings Call Transcript

    Financial Performance

    • INOX Wind Q1 FY27: revenue INR872 cr, EBITDA INR237 cr, PBT INR95 cr, PAT INR64 cr.
    • Cash profit for INOX Wind: INR153 cr in Q1 FY27.
    • Order book stands at ~4.4 GW as of July 2026; equipment share ~59%.
    • NLC India LOA for 200 MW received.
    • MOU for 1.5 GW with INOX Clean; 500 MW firm orders so far.
    • Prototype 4X turbine to be installed August; commercial launch by end FY26.
    • Demerger of the power evacuation infrastructure business from INOX Green into INOX Renewable Solution has been completed as on August 1, 2026.
    • INOX Green Q1 FY27 total income INR101 cr; EBITDA INR57 cr.
    • O&M portfolio stood at 13.3 GW as of June 2026.
    • Wind capacity installed in India 57.4 GW as of June 2026.
    • NCLT Wind World India acquisition completion expected in Q2 FY27.
    • RESCO listing: record date completed; timing to list soon; no forward guidance.
    • ALMM indigenization: 80-90% components; aim 100% by year-end.
    • H2 accounts for 70-75% of annual revenue; guidance remains 75% YoY growth.
    • FY27 annual EBITDA guidance INR600 crores; not a quarterly target.
    • Receivables to improve as pivot to equipment supply; days expected to decline in 3–4 quarters.

    Operating Update

    • Jaipur transformer factory to manufacture 4.9 MVA transformers; expand to 8-20 MVA, 100 MVA+.
    • We own 4 cranes; more to come this financial year.
    • High-value power electronics like inverters, unit substations, capacitor systems; USS commercially launched in FY27.
    • 4 GW wind capacity commissioned in Q1 FY27.
    • Wind World India O&M portfolio stands at ~4.5 GW; FY26 revenue ~INR 580 cr; 5% escalations.
    • Total installed wind capacity in India 57.4 GW as of June 2026; 8-10 GW/year additions expected.

    Guidance and Outlook

    • Full-year revenue growth guidance: 75% YoY; consolidated EBITDA margin 20-22%.
    • H2 typically accounts for 70-75% of annual revenue; guidance remains 75% YoY growth.
    • FY27 EBITDA target INR600 crores annualized after consolidation; impact from Q3 FY27.
    • ALMM indigenization: 80-90% components; aim 100% by year-end.
    • RESCO listing timing to be guided near listing; record date completed.

    Q&A Highlights

    • Pivot to equipment supply causes near-term softness; expects H2 lift and full-year target.
    • 4X model launch by August; commercial activity starting a month later.
    • Receivables to improve as pivot to equipment; days to decline in 3–4 quarters.
    • About 40% third-party orders turnkey; 1.5 GW MOU with INOX Clean; 200 MW LOA from NLC.

    Risks and Watchpoints

    • Execution risk from large backlog and consolidation timeline.
    • Force majeure events could impact timelines; management cited external risks.
    • Silent period limits forward guidance beyond public disclosures.
    • EPC exposure and dependence on group entities; terms are intended to be arm's length.
    Read the primary exchange filing